source
- Novartis' $12 billion Avidity drug fails Phase 3 trial in myotonic dystrophyNovartis reported that its antibody-oligonucleotide conjugate del-desiran did not meet the primary endpoint in the Phase 3 HARBOR study for myotonic dystrophy type 1, showing no significant improve…
- Moderna and Merck’s personalized mRNA cancer vaccine success spurs industry shift to faster, smaller-scale productionAfter mastering large‑scale mRNA manufacturing during the COVID‑19 pandemic, the sector is now turning its attention to delivering individualized vaccines to patients quickly. The recent clinical…